Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells

Funke C, Farr M, Werner B, Dittmann S, Überla K, Piper C, Niehaus K, Horstkotte D (2010)
Journal of General Virology 91(8): 1959-1970.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Autor/in
; ; ; ; ; ; ;
Abstract / Bemerkung
In viral myocarditis, adeno- and enteroviruses have most commonly been implicated as causes of infection. Both viruses require the human coxsackie-adenovirus receptor (CAR) to infect the myocardium. Due to its crucial role for viral entry, CAR-downregulation may lead to novel approaches for treatment for viral myocarditis. In this study, we report on pharmaceutical drug influences on CAR levels in human umbilical vein endothelial cells (HUVEC) and cervical carcinoma cells (HeLa) detected by immunoblotting, quantitative real time-PCR and cellular susceptibility to the cardiotropic coxsackie-B3 virus strain Nancy (CVB3). Our results indicate, for the first time, a dose-dependent CAR mRNA and protein downregulation upon Valsartan and Bosentan treatment. Most interestingly, drug-induced CAR diminution significantly reduced the viral load in CVB3-infected HUVEC. In order to assess the regulatory effects of both drugs in detail, we knocked down their protein targets, the G-protein coupled receptors angiotensin-II type-1 receptor (AT(1)R) and endothelin-1 type-A and -B receptors (ETAR/ETBR) in HUVEC. Receptor-specific gene silencing indicates that CAR gene expression is regulated by agonistic and antagonistic binding to ETBR, but not ETAR. In addition, neither stimulation nor inhibition of AT(1)R seemed to be involved in CAR gene regulatory processes. Our study indicates that Valsartan and Bosentan protected human endothelial cells from CVB3-infection. Therefore, besides their well-known anti-hypertensive effects these drugs may also protect the myocardium and other tissues from coxsackie- and adenoviral infection.
Erscheinungsjahr
2010
Zeitschriftentitel
Journal of General Virology
Band
91
Ausgabe
8
Seite(n)
1959-1970
ISSN
0022-1317
eISSN
1465-2099
Page URI
https://pub.uni-bielefeld.de/record/1794304

Zitieren

Funke C, Farr M, Werner B, et al. Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. Journal of General Virology. 2010;91(8):1959-1970.
Funke, C., Farr, M., Werner, B., Dittmann, S., Überla, K., Piper, C., Niehaus, K., et al. (2010). Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. Journal of General Virology, 91(8), 1959-1970. doi:10.1099/vir.0.020065-0
Funke, C., Farr, M., Werner, B., Dittmann, S., Überla, K., Piper, C., Niehaus, K., and Horstkotte, D. (2010). Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. Journal of General Virology 91, 1959-1970.
Funke, C., et al., 2010. Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. Journal of General Virology, 91(8), p 1959-1970.
C. Funke, et al., “Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells”, Journal of General Virology, vol. 91, 2010, pp. 1959-1970.
Funke, C., Farr, M., Werner, B., Dittmann, S., Überla, K., Piper, C., Niehaus, K., Horstkotte, D.: Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. Journal of General Virology. 91, 1959-1970 (2010).
Funke, Carsten, Farr, Martin, Werner, Bianca, Dittmann, Sven, Überla, Klaus, Piper, Cornelia, Niehaus, Karsten, and Horstkotte, Dieter. “Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells”. Journal of General Virology 91.8 (2010): 1959-1970.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 20392896
PubMed | Europe PMC

Suchen in

Google Scholar